{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"will be assessed by both MRI and by pathologic review after surgery. An estimate of each response rate and the 95% CI will be provided","groups":[{"description":"Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib","id":"OG000","title":"Pazopanib 400 mg QD"}],"populationDescription":"No data is available because data was not collected due to lack of accrual.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Pathologic Response","type":"SECONDARY"}